Prophylaxis days (with or without having receiving fluconazole during any prophylaxis period) was 1,650 days within the echinocandin group (ratio of 43 days per patient) versus 3,164 days within the anti-Aspergillus azole group (ratio of 75 days per patient). The majority (84/152, 55 ) of sufferers who received voriconazole prophylaxis in our study received the oral formulation, representing 98 of voriconazole prophylaxis days (four,193/4,266 days). The frequencies of overlapping periods of fluconazole have been comparable in patients receiving echinocandin versus voriconazole/posaconazole prophylaxis (50 versus 31 , respectively, P 0.11), and also the durations of fluconazole prophylaxis for the two groups were equivalent. The median time for you to initiate antiAspergillus drug class after initially remission-induction chemotherapy was 2 days significantly less inside the echinocandin group than in the voriconazole/posaconazole group (medians of 1 and 3 days; P 0.04). The frequency of documented IFI, in unique, invasive candidiasis, was larger amongst individuals who received only echinocandin versus anti-Aspergillus azole-based prophylaxis (8 versus 0 , P 0.09). To examine prices of IFI amongst sufferers, such as people that switched antifungal prophylaxis during the study period (n 45 sufferers), we constructed Kaplan-Meier curves for the probability of becoming totally free of IFI stratified by antifungal prophylaxis as a time-dependent covariate (Fig. 2). Marked differences inside the probability of getting IFI cost-free have been evident in between individuals who received key antifungal prophylaxis with voriconazole or posaconazole and sufferers who received an echinocandin, despite the fact that the prices of empirical antifungal therapy use by the two prophylaxis groups had been similar (32 versus 40 , P 0.41). All-cause mortality prices didn’t differ between the echinocandinaac.asm.orgAntimicrobial Agents and ChemotherapyPredictive Variables for Fungal InfectionTABLE 1 Candidate threat variables for documented IFI in individuals with AML through first 120 days just after initial remission-induction chemotherapyDemographicp Male, n ( ) Median age (IQR), yrs Hospitalizationb Median no. of hospitalizations (IQR) Median duration (IQR), days Admission to the HEPA filter room, n ( ) Underlying circumstances, n ( ) Lung disease or infectiond Concomitant bacterial infectione Cardiovascular disease or condition Diabetes mellitus or hyperglycemiaf History of renal failure or renal dysfunctiong Abnormal liver testsh No.ISX-3 ( ) with other malignancyi No.Cefotaxime sodium salt ( ) chemotherapy naive WHO AML classification,j n ( ) Therapy-related AML MDS-related modifications Recurrent genetic abnormalities Myeloid sarcoma Acute leukemia of ambiguous lineage Not specified Cytogenetic threat group,k n ( ) Favorable Intermediate I Intermediate II Adverse Remission-induction chemotherapy, n ( ) Cytarabine-based regimen Other regimen Investigational chemotherapyl Clofarabine-based regimenm Overall remission All round remission, n ( )n Neutropenia Neutropenia at begin of prophylaxis, n ( ) Median no.PMID:23903683 of episodes of neutropenia (IQR) Median duration of neutropenia (IQR), dayso Major antifungal prophylaxis Anti-Aspergillus azole (voriconazole or posaconazole)cTABLE 1 (Continued)Demographicp Documented IFI (n 21) 10 (48) 19 (135) No IFI (n 104) 77 (74) 75 (2901) P valueaDocumented IFI (n 21) 7 (33) 63 (570) 1 (1) 21 (149) eight (38)No IFI (n 104) 62 (60) 65 (513) two (1) 31 (229) 35 (34)P valuea 0.05 0.7 0.0.five (24) five (24) eight (38) five (24) 1 (five) two (10) 7 (33) 16/21 (80)26 (25) 15 (14) 32 (31) 18 (17) 15 (14) 13 (13.